Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Yeung

Neurology Loma Linda, CA Doctor of Osteopathy

NPI 1659663276 CMS profile 609629

11370 Anderson St Ste B-100, Loma Linda, CA 92354

Open in the dashboard

General payments

$255,733

348 records reported · program years 2019–2025

Research payments

$356

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$253,208 paid to institutions, not to them · program years 2020–2022

Through program year 2025, Stephen Yeung of Loma Linda, CA is reported in the CMS Open Payments database as having received $255,733 across 348 general payments and $356 in research payments paid to them. Separately, studies naming them as principal investigator received $253,208 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $226 3
2024 General $90 1
2023 General $332 3
2022 General $255 4
2021 General $54,432 47
2021 Research $356 1
2020 General $71,306 110
2019 General $129,091 180

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Yeung
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Stephen Yeung were reported at $226. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Stephen Yeung Neurology median Middle half National median
2019 $129,091 $474 $118–$2,177 $163
2020 $71,306 $367 $82–$2,309 $114
2021 $54,432 $438 $104–$2,547 $132
2022 $255 $442 $103–$2,388 $149
2023 $332 $464 $119–$2,312 $160
2024 $90 $468 $119–$2,323 $164
2025 $226 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $134,839 185 payments
  2. Biogen, Inc. $53,860 61 payments
  3. Novartis Pharma AG $25,260 4 payments
  4. EMD Serono, Inc. $14,567 32 payments
  5. Genzyme Corporation $12,583 26 payments
  6. Genentech USA, Inc. $8,058 7 payments
  7. Alexion Pharmaceuticals, Inc. $3,900 19 payments
  8. Celgene Corporation $1,200 2 payments
  9. Genentech, Inc. $1,036 2 payments
  10. Horizon Therapeutics plc $143 2 payments
  11. Other $286 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $147,027 72 payments
  2. Consulting Fee $63,692 22 payments
  3. Travel and Lodging $35,221 74 payments
  4. Food and Beverage $9,742 179 payments
  5. Education $51 1 payment
Products named General payments · program years 2019–2025
  1. MAYZENT $130,302 139 payments
  2. VUMERITY $28,566 21 payments
  3. TYSABRI $23,094 35 payments
  4. KESIMPTA $13,527 23 payments
  5. TECFIDERA $9,661 19 payments
  6. Mavenclad Neurology $8,351 16 payments
  7. OCREVUS $8,079 8 payments
  8. GILENYA $6,859 9 payments
  9. AUBAGIO $6,669 11 payments
  10. Mavenclad Neurology $6,165 15 payments
  11. Other $12,222 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $356 1 payment

Records

349 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record